ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2024-4-2-3-12ppan-99Research ArticleREVIEWDiagnostic Value of Short-chain Fatty Acids in Psychoneurology and Methodological Aspects of Quantitative AssessmentKupriyanovaO. V.

Olga V. Kupriyanova

420008, Kazan; 420012, Kazan

public.mail@kpfu.ruGrigoryevaT. V.

Tatiana V. Grigoryeva 

420008, Kazan

tatabio@inbox.ruKazan (Volga Region) Federal University; Kazan State Medical UniversityRussian FederationKazan (Volga Region) Federal UniversityRussian Federation20241806202442312Copyright © Kupriyanova O.V., Grigoryeva T.V., 20242024Kupriyanova O.V., Grigoryeva T.V.Kupriyanova O.V., Grigoryeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/99

Increasing evidence suggests that bidirectional communication between the gut microbiome and the central nervous system, also known as the microbiota-gut-brain axis, plays a key role in brain development and function. Short-chain fatty acids (SCFAs), as one of the main microbial metabolites, have a broad multifactorial effect on many physiological and pathophysiological processes in the body, including the central nervous system. It is known that there are correlations between the phenotype of patients with a nervous system disorder and the SCFAs profile. Currently, the most informative and reliable method for the quantitative assessment of SCFAs is gas chromatography (GC), however, such studies of the SCFAs profile in the case of diseases of the nervous system are limited, and until now scientific experience in this area has not been generalized. In this regard, the purpose of this review is to summarize the diagnostic value of SCFAs profile in the case of nervous and mental disorders, as well as to demonstrate the capabilities of gas chromatography for studying the metabolic profile of these diseases.

short-chain fatty acidsintestinal microbiotagas chromatographymetabolomic profilingmolecular diagnos-ticsneuropsychiatric disordersThis research was funded by the subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities (#FZSM-2023-0013).ReferencesSorboni, G.S.; Moghaddam, H.S.; Jafarzadeh-Esfehani, R.; Soleimanpour, S. Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Clinical Microbiology Reviews 2022, 35(1):e0033820. doi: 10.1128/CMR.00338-20.Sorboni, G.S.; Moghaddam, H.S.; Jafarzadeh-Esfehani, R.; Soleimanpour, S. Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Clinical Microbiology Reviews 2022, 35(1):e0033820. doi: 10.1128/CMR.00338-20.Doroszkiewicz, J.; Groblevska, M.; Mroczko, B. The role of gut microbiota and gut-brain interplay in selected diseases of the central nervous system. International Journal of Molecular Sciences 2021, 22(18):10028. doi: 10.3390/ijms221810028.Doroszkiewicz, J.; Groblevska, M.; Mroczko, B. The role of gut microbiota and gut-brain interplay in selected diseases of the central nervous system. International Journal of Molecular Sciences 2021, 22(18):10028. doi: 10.3390/ijms221810028.Ahmed, H.; Leyrolle, Q.; Koistinen, V. et al. Microbiota-derived metabolites as drivers of gut–brain communication. Gut microbes 2022, 1 4(1):2102878. doi: 10.1080/19490976.2022.2102878.Ahmed, H.; Leyrolle, Q.; Koistinen, V. et al. Microbiota-derived metabolites as drivers of gut–brain communication. Gut microbes 2022, 1 4(1):2102878. doi: 10.1080/19490976.2022.2102878.Dinan, T.G.; Cryan, J.F. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterology Clinics of North America 2017, 46(1):77-89. doi: 10.1016/j.gtc.2016.09.007.Dinan, T.G.; Cryan, J.F. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterology Clinics of North America 2017, 46(1):77-89. doi: 10.1016/j.gtc.2016.09.007.Liu, P.; Peng, G.; Zhang, N. et al. Crosstalk between the gut microbiota and the brain: an update on neuroimaging findings. Front. Neurol. 2019, 10:883. doi: 10.3389/fneur.2019.00883.Liu, P.; Peng, G.; Zhang, N. et al. Crosstalk between the gut microbiota and the brain: an update on neuroimaging findings. Front. Neurol. 2019, 10:883. doi: 10.3389/fneur.2019.00883.Wang, B.; Yao, M.; Lv, L. et al. The human microbiota in health and disease. Engineering 2017, 3(10):71-82. DOI:10.1016/J.ENG.2017.01.008Wang, B.; Yao, M.; Lv, L. et al. The human microbiota in health and disease. Engineering 2017, 3(10):71-82. DOI:10.1016/J.ENG.2017.01.008Priori, D.; Colombo, M.; Clavenzani, P. et al. The Olfactory Receptor OR51E1 Is Present along the Gastrointestinal Tract of Pigs, Co-Localizes with Enteroendocrine Cells and Is Modulated by Intestinal Microbiota. PLoS ONE 2015, 10(6):e0129501. doi: 10.1371/journal.pone.0129501.Priori, D.; Colombo, M.; Clavenzani, P. et al. The Olfactory Receptor OR51E1 Is Present along the Gastrointestinal Tract of Pigs, Co-Localizes with Enteroendocrine Cells and Is Modulated by Intestinal Microbiota. PLoS ONE 2015, 10(6):e0129501. doi: 10.1371/journal.pone.0129501.Strandwitz, P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018, 1693, 128-133. doi: 10.1016/j.brainres.2018.03.015.Strandwitz, P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018, 1693, 128-133. doi: 10.1016/j.brainres.2018.03.015.Caspani, G.; Swann, J. Small talk: Microbial metabolites involved in the signaling from microbiota to brain. Curr. Opin. Pharmacol. 2019; 48, 99-106. doi: 10.1016/j.coph.2019.08.001.Caspani, G.; Swann, J. Small talk: Microbial metabolites involved in the signaling from microbiota to brain. Curr. Opin. Pharmacol. 2019; 48, 99-106. doi: 10.1016/j.coph.2019.08.001.Tolhurst, G.; Heffron, H.; Lam, Y.S. et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2. Diabetes 2012, 61, 364–371. doi: 10.2337/db11-1019.Tolhurst, G.; Heffron, H.; Lam, Y.S. et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2. Diabetes 2012, 61, 364–371. doi: 10.2337/db11-1019.Generoso, J.S.; Giridharan, V.V.; Lee, J. et al. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry 2021, 43, 293-305. doi: 10.1590/1516-4446-2020-0987.Generoso, J.S.; Giridharan, V.V.; Lee, J. et al. The role of the microbiota-gut-brain axis in neuropsychiatric disorders. Braz J Psychiatry 2021, 43, 293-305. doi: 10.1590/1516-4446-2020-0987.den Besten, G.; van Eunen, K.; Groen, A.K. et al. The role of short-chain fatty acids in the interplay between diet, gut micro-biota, and host energy metabolism. J. Lipid Res. 2013, 54, 2325-2340. doi: 10.1194/jlr.R036012.den Besten, G.; van Eunen, K.; Groen, A.K. et al. The role of short-chain fatty acids in the interplay between diet, gut micro-biota, and host energy metabolism. J. Lipid Res. 2013, 54, 2325-2340. doi: 10.1194/jlr.R036012.Plöger, S.; Stumpff, F.; Penner, G.B. et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann. N. Y. Acad. Sci. 2012, 1258, 52–59. doi: 10.1111/j.1749-6632.2012.06553.x.Plöger, S.; Stumpff, F.; Penner, G.B. et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann. N. Y. Acad. Sci. 2012, 1258, 52–59. doi: 10.1111/j.1749-6632.2012.06553.x.Stilling, R.M.; van de Wouw, M.; Clarke, G. et al. The neuropharmacology of butyrate: the bread and butter of the microbi-ota-gut-brain axis? Neurochem Int. 2016, 99, 110-132. doi: 10.1016/j.neuint.2016.06.011.Stilling, R.M.; van de Wouw, M.; Clarke, G. et al. The neuropharmacology of butyrate: the bread and butter of the microbi-ota-gut-brain axis? Neurochem Int. 2016, 99, 110-132. doi: 10.1016/j.neuint.2016.06.011.Funato, H.; Oda, S.; Yokofujita, J. et al. Fasting and High-Fat Diet Alter Histone Deacetylase Expression in the Medial Hy-pothalamus. PLoS ONE 2011, 6(4):e18950. doi: 10.1371/journal.pone.0018950.Funato, H.; Oda, S.; Yokofujita, J. et al. Fasting and High-Fat Diet Alter Histone Deacetylase Expression in the Medial Hy-pothalamus. PLoS ONE 2011, 6(4):e18950. doi: 10.1371/journal.pone.0018950.Kim, H.J.; Leeds, P.; Chuang, D.M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem. 2009, 110(4):1226-40. doi: 10.1111/j.1471-4159.2009.06212.x.Kim, H.J.; Leeds, P.; Chuang, D.M. The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain. J Neurochem. 2009, 110(4):1226-40. doi: 10.1111/j.1471-4159.2009.06212.x.Hahnen, E.; Hauke, J.; Tränkle, C. et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disor-ders. Expert Opinion on Investigational Drugs 2008, 17, 169–184. doi: 10.1517/13543784.17.2.169.Hahnen, E.; Hauke, J.; Tränkle, C. et al. Histone deacetylase inhibitors: possible implications for neurodegenerative disor-ders. Expert Opinion on Investigational Drugs 2008, 17, 169–184. doi: 10.1517/13543784.17.2.169.Xu, K.; Dai, X.L.; Huang, H.C. et al. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev. 2011, 2011:143269. doi: 10.1155/2011/143269.Xu, K.; Dai, X.L.; Huang, H.C. et al. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev. 2011, 2011:143269. doi: 10.1155/2011/143269.Donohoe, D.R.; Garge, N.; Zhang, X. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011, 13, 517–526. doi: 10.1016/j.cmet.2011.02.018.Donohoe, D.R.; Garge, N.; Zhang, X. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 2011, 13, 517–526. doi: 10.1016/j.cmet.2011.02.018.Brahe, L.K.; Astrup, A.; Larsen, L.H. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev. 2013, 14, 950–959. doi: 10.1111/obr.12068.Brahe, L.K.; Astrup, A.; Larsen, L.H. Is butyrate the link between diet, intestinal microbiota and obesity-related metabolic diseases? Obes Rev. 2013, 14, 950–959. doi: 10.1111/obr.12068.Li, L.; Ma, L.; Fu, P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 2017, 11, 3531–3542. doi: 10.2147/DDDT.S150825.Li, L.; Ma, L.; Fu, P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 2017, 11, 3531–3542. doi: 10.2147/DDDT.S150825.Unger, M.M.; Spiegel, J.; Dillmann, K. et al. Short chain fatty acids and gut microbiota differ between patients with Parkin-son's disease and age-matched controls. Parkinsonism and Related Disorders. 2016, 32, 66-72. doi: 10.1016/j.parkreldis.2016.08.019.Unger, M.M.; Spiegel, J.; Dillmann, K. et al. Short chain fatty acids and gut microbiota differ between patients with Parkin-son's disease and age-matched controls. Parkinsonism and Related Disorders. 2016, 32, 66-72. doi: 10.1016/j.parkreldis.2016.08.019.Tan, A.H. et al. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics. Annals of Neurology 2021, 89, 546–559. doi: 10.1002/ana.25982.Tan, A.H. et al. Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi‐Omics. Annals of Neurology 2021, 89, 546–559. doi: 10.1002/ana.25982.Shin, С.; Lim, Y.; Lim, H.; Ahn, T.B. Plasma Short-Chain Fatty Acids in Patients With Parkinson’s Disease. Movement Disor-ders 2020, 35, 1021-1027. doi: 10.1002/mds.28016.Shin, С.; Lim, Y.; Lim, H.; Ahn, T.B. Plasma Short-Chain Fatty Acids in Patients With Parkinson’s Disease. Movement Disor-ders 2020, 35, 1021-1027. doi: 10.1002/mds.28016.Yang, X.; Ai, P.; He, X.; Mo, C.; Zhang, Y.; Xu, S.; Lai, Y.; Qian, Y.; Xiao, Q. Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids. Movement Disorders 2022, 37, 1634-1643. doi: 10.1002/mds.29063.Yang, X.; Ai, P.; He, X.; Mo, C.; Zhang, Y.; Xu, S.; Lai, Y.; Qian, Y.; Xiao, Q. Parkinson's Disease Is Associated with Impaired Gut-Blood Barrier for Short-Chain Fatty Acids. Movement Disorders 2022, 37, 1634-1643. doi: 10.1002/mds.29063.He, X.; Qian, Y.; Xu, S.; Zhang, Y.; Mo, C.; Guo, W.; Yang, X.; Xiao, Q. Plasma Short-Chain Fatty Acids Differences in Multi-ple System Atrophy from Parkinson’s Disease. Journal of Parkinson’s Disease 2021, 11, 1167–1176. doi: 10.3233/JPD-212604.He, X.; Qian, Y.; Xu, S.; Zhang, Y.; Mo, C.; Guo, W.; Yang, X.; Xiao, Q. Plasma Short-Chain Fatty Acids Differences in Multi-ple System Atrophy from Parkinson’s Disease. Journal of Parkinson’s Disease 2021, 11, 1167–1176. doi: 10.3233/JPD-212604.Ho, L.; Ono, K.; Tsuji, M. et al. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s dis-ease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother 2018, 18, 83-90. doi: 10.1080/14737175.2018.1400909.Ho, L.; Ono, K.; Tsuji, M. et al. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s dis-ease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother 2018, 18, 83-90. doi: 10.1080/14737175.2018.1400909.Nicholson, J.K.; Holmes, E.; Kinross, J. et al. Host-gut microbiota metabolic interactions. Science 2012, Volume 336, p. 1262-1267. doi: 10.1126/science.1223813.Nicholson, J.K.; Holmes, E.; Kinross, J. et al. Host-gut microbiota metabolic interactions. Science 2012, Volume 336, p. 1262-1267. doi: 10.1126/science.1223813.Zilberter, Y.; Zilberter, M. The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. J Neurosci Res. 2017, 95, 2217-2235. doi: 10.1002/jnr.24064.Zilberter, Y.; Zilberter, M. The vicious circle of hypometabolism in neurodegenerative diseases: Ways and mechanisms of metabolic correction. J Neurosci Res. 2017, 95, 2217-2235. doi: 10.1002/jnr.24064.Marizzoni. M.; Cattaneo, A.; Mirabelli, P. et al. Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer’s Disease. Journal of Alzheimer’s Disease 2020, 78, 683-697. doi: 10.3233/JAD-200306.Marizzoni. M.; Cattaneo, A.; Mirabelli, P. et al. Short-Chain Fatty Acids and Lipopolysaccharide as Mediators Between Gut Dysbiosis and Amyloid Pathology in Alzheimer’s Disease. Journal of Alzheimer’s Disease 2020, 78, 683-697. doi: 10.3233/JAD-200306.Ubeda, C.; Vázquez-Carretero, M.D.; Luque-Tirado, A.; Ríos-Reina, R.; Rubio-Sánchez, R.; Franco-Macías, E.; Gar-cía-Miranda, P.; Calonge, M.L.; Peral, M.J. Fecal Volatile Organic Compounds and Microbiota Associated with the Progres-sion of Cognitive Impairment in Alzheimer’s Disease. Int. J. Mol. Sci. 2023, 24(1):707. doi: 10.3390/ijms24010707.Ubeda, C.; Vázquez-Carretero, M.D.; Luque-Tirado, A.; Ríos-Reina, R.; Rubio-Sánchez, R.; Franco-Macías, E.; Gar-cía-Miranda, P.; Calonge, M.L.; Peral, M.J. Fecal Volatile Organic Compounds and Microbiota Associated with the Progres-sion of Cognitive Impairment in Alzheimer’s Disease. Int. J. Mol. Sci. 2023, 24(1):707. doi: 10.3390/ijms24010707.Wu, L.; Han, Y.; Zheng, Z.; Peng, G.; Liu, P.; Yue, S.; Zhu, S.; Chen, J.; Lv, H.; Shao, L.; Sheng, Y.; Wang, Y.; Li, L.; Li, L.; Wang, B. Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Signals in Host–Microbe Interplay. Nutrients 2021, 13(1):228. doi: 10.3390/nu13010228.Wu, L.; Han, Y.; Zheng, Z.; Peng, G.; Liu, P.; Yue, S.; Zhu, S.; Chen, J.; Lv, H.; Shao, L.; Sheng, Y.; Wang, Y.; Li, L.; Li, L.; Wang, B. Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: Signals in Host–Microbe Interplay. Nutrients 2021, 13(1):228. doi: 10.3390/nu13010228.Liu, S.; Li, E.; Sun, Zh.; Fu, D.; Duan, G.; Jiang, M.; Yu, Y.; Mei, L.; Yang, P.; Tang, Y.; Zheng, P. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Scientific Reports 2019, 9. doi:10.1038/s41598-018-36430-z.Liu, S.; Li, E.; Sun, Zh.; Fu, D.; Duan, G.; Jiang, M.; Yu, Y.; Mei, L.; Yang, P.; Tang, Y.; Zheng, P. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Scientific Reports 2019, 9. doi:10.1038/s41598-018-36430-z.Calliope, H.; Carol, N.; Lee, Li.C. et al. Gastrointestinal symptoms in autism spectrum disorder: A review of the literature on ascertainment and prevalence. Autism Res. 2017, Volume 11, p. 4-36. doi: 10.1002/aur.1854.Calliope, H.; Carol, N.; Lee, Li.C. et al. Gastrointestinal symptoms in autism spectrum disorder: A review of the literature on ascertainment and prevalence. Autism Res. 2017, Volume 11, p. 4-36. doi: 10.1002/aur.1854.Adams, J.B.; Johansen, L.J.; Powell, L.D. et al. Gastrointestinal flora and gastrointestinal status in children with autism–comparisons to typical children and correlation with autism severity. BMC Gastroenterology 2011, 11:22. doi: 10.1186/1471-230X-11-22.Adams, J.B.; Johansen, L.J.; Powell, L.D. et al. Gastrointestinal flora and gastrointestinal status in children with autism–comparisons to typical children and correlation with autism severity. BMC Gastroenterology 2011, 11:22. doi: 10.1186/1471-230X-11-22.Wang, L.; Christophersen, C.T.; Sorich, M.J. et al. Elevated Fecal Short Chain Fatty Acid and Ammonia Concentrations in Children with Autism Spectrum Disorder. Digestive Diseases and Sciences 2012, 57(8):2096-2102. doi: 10.1007/s10620-012-2167-7.Wang, L.; Christophersen, C.T.; Sorich, M.J. et al. Elevated Fecal Short Chain Fatty Acid and Ammonia Concentrations in Children with Autism Spectrum Disorder. Digestive Diseases and Sciences 2012, 57(8):2096-2102. doi: 10.1007/s10620-012-2167-7.Al-Lahham, S.H.; Peppelenbosch, M.P.; Roelofsen, H. et al. Biological effects of propionic acid in humans; metabolism, po-tential applications and underlying mechanisms. Biochim. Biophys. Acta. 2010, 1801, 1175–1183. doi: 10.1016/j.bbalip.2010.07.007.Al-Lahham, S.H.; Peppelenbosch, M.P.; Roelofsen, H. et al. Biological effects of propionic acid in humans; metabolism, po-tential applications and underlying mechanisms. Biochim. Biophys. Acta. 2010, 1801, 1175–1183. doi: 10.1016/j.bbalip.2010.07.007.Kratsman, N.; Getselter, D.; Elliott, E. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology 2016, 102, 136–145. doi: 10.1016/j.neuropharm.2015.11.003.Kratsman, N.; Getselter, D.; Elliott, E. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology 2016, 102, 136–145. doi: 10.1016/j.neuropharm.2015.11.003.Ristori, M.V.; Quagliariello, A.; Reddel, S. Autism, Gastrointestinal Symptoms and Modulation of Gut Microbiota by Nutri-tional Interventions. Nutrients 2019, 11(11):2812. doi: 10.3390/nu11112812.Ristori, M.V.; Quagliariello, A.; Reddel, S. Autism, Gastrointestinal Symptoms and Modulation of Gut Microbiota by Nutri-tional Interventions. Nutrients 2019, 11(11):2812. doi: 10.3390/nu11112812.Taniya, M.A.; Chung, H.J.; Mamun, A.Al. et al. Role of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation. Frontiers in Cellular and Infection Microbiology 2022, 12:915701. doi: 10.3389/fcimb.2022.915701.Taniya, M.A.; Chung, H.J.; Mamun, A.Al. et al. Role of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation. Frontiers in Cellular and Infection Microbiology 2022, 12:915701. doi: 10.3389/fcimb.2022.915701.Zhao, G.; Liu, J.F.; Nyman, M.; Jonsson, J.A. Determination of short-chain fatty acids in serum by hollow fiber supported liquid membrane extraction coupled with gas chromatography. J Chromatogr B 2007, 846(1-2):202-208. doi: 10.1016/j.jchromb.2006.09.027.Zhao, G.; Liu, J.F.; Nyman, M.; Jonsson, J.A. Determination of short-chain fatty acids in serum by hollow fiber supported liquid membrane extraction coupled with gas chromatography. J Chromatogr B 2007, 846(1-2):202-208. doi: 10.1016/j.jchromb.2006.09.027.Kim, S.W.; Hooker, J.M.; Otto, N. et al. Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nucl Med Biol. 2013, 40(7):912-8. doi: 10.1016/j.nucmedbio.2013.06.007.Kim, S.W.; Hooker, J.M.; Otto, N. et al. Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET. Nucl Med Biol. 2013, 40(7):912-8. doi: 10.1016/j.nucmedbio.2013.06.007.Li, X.; Fan, X.; Yuan, X. et al. The Role of Butyric Acid in Treatment Response in Drug-Naive First Episode Schizophrenia. Front. Psychiatry 2021, 12:724664. doi: 10.3389/fpsyt.2021.724664.Li, X.; Fan, X.; Yuan, X. et al. The Role of Butyric Acid in Treatment Response in Drug-Naive First Episode Schizophrenia. Front. Psychiatry 2021, 12:724664. doi: 10.3389/fpsyt.2021.724664.Li, X., Yuan, X.; Pang, L. et al. The effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naïve, first episode schizophrenia patients. Psychiatry Res. 2022, 313:114582. doi: 10.1016/j.psychres.2022.114582.Li, X., Yuan, X.; Pang, L. et al. The effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naïve, first episode schizophrenia patients. Psychiatry Res. 2022, 313:114582. doi: 10.1016/j.psychres.2022.114582.Perry, T.L.; Hansen, S.; Diamond, S. et al. Acetic and benzoic acids in the urine of patients with chronic schizophrenia. Clin. Chim. Acta. 1971, 31(1):181-6. doi: 10.1016/0009-8981(71)90376-7.Perry, T.L.; Hansen, S.; Diamond, S. et al. Acetic and benzoic acids in the urine of patients with chronic schizophrenia. Clin. Chim. Acta. 1971, 31(1):181-6. doi: 10.1016/0009-8981(71)90376-7.Konanov, D.N.; Zakharzhevskaya, N.B.; Kardonsky, D.A. et al. UniqPy: A tool for estimation of short-chain fatty acids composition by gas-chromatography/mass-spectrometry with headspace extraction. Journal of Pharmaceutical and Biomedical Analysis 2022, 212:114681. doi: 10.1016/j.jpba.2022.114681.Konanov, D.N.; Zakharzhevskaya, N.B.; Kardonsky, D.A. et al. UniqPy: A tool for estimation of short-chain fatty acids composition by gas-chromatography/mass-spectrometry with headspace extraction. Journal of Pharmaceutical and Biomedical Analysis 2022, 212:114681. doi: 10.1016/j.jpba.2022.114681.Yao, L.; Davidson, E.A.; Shaikh, M.W. et al. Quantitative analysis of short chain fatty acids in human plasma and serum by GC–MS. Analytical and Bioanalytical Chemistry 2022, 414, 4391–4399. doi: 10.1007/s00216-021-03785-8.Yao, L.; Davidson, E.A.; Shaikh, M.W. et al. Quantitative analysis of short chain fatty acids in human plasma and serum by GC–MS. Analytical and Bioanalytical Chemistry 2022, 414, 4391–4399. doi: 10.1007/s00216-021-03785-8.Rahman, M.N.; Diantini, A.; Fattah, M. et al. A highly sensitive, simple, and fast gas chromatography–mass spectrometry method for the quantification of serum short-chain fatty acids and their potential features in central obesity. Analytical and Bioanalytical Chemistry 2021, 413, 6837–6844. doi: 10.1007/s00216-021-03639-3.Rahman, M.N.; Diantini, A.; Fattah, M. et al. A highly sensitive, simple, and fast gas chromatography–mass spectrometry method for the quantification of serum short-chain fatty acids and their potential features in central obesity. Analytical and Bioanalytical Chemistry 2021, 413, 6837–6844. doi: 10.1007/s00216-021-03639-3.Skonieczna-Żydecka, K.; Grochans, E.; Maciejewska, D. et al. Faecal Short Chain Fatty Acids Profile is Changed in Polish Depressive Women. Nutrients 2018, 10(12):1939. doi: 10.3390/nu10121939.Skonieczna-Żydecka, K.; Grochans, E.; Maciejewska, D. et al. Faecal Short Chain Fatty Acids Profile is Changed in Polish Depressive Women. Nutrients 2018, 10(12):1939. doi: 10.3390/nu10121939.Borgo, F.; Riva, A.; Benetti, A. et al. Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. PLOS ONE 2017, 12(6):e0179739. doi: 10.1371/journal.pone.0179739.Borgo, F.; Riva, A.; Benetti, A. et al. Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests. PLOS ONE 2017, 12(6):e0179739. doi: 10.1371/journal.pone.0179739.Zhang, S.; Wang, H.; Zhu, M.J. A sensitive GC/MS detection method for analyzing microbial metabolites short chain fatty acids in fecal and serum samples. Talanta 2019, 196:249-254. doi: 10.1016/j.talanta.2018.12.049.Zhang, S.; Wang, H.; Zhu, M.J. A sensitive GC/MS detection method for analyzing microbial metabolites short chain fatty acids in fecal and serum samples. Talanta 2019, 196:249-254. doi: 10.1016/j.talanta.2018.12.049.

The authors declare that there are no conflicts of interest present.